Individuals (n = 39) participated in an outpatient, 16-session individual, manual-guided psychotherapy designed to treat concurrent PTSD and cocaine dependence. Therapy consisted of a combination of imaginal and in-vivo exposure therapy techniques to treat PTSD symptoms and cognitive-behavioral techniques to treat cocaine dependence. Although the dropout rate was high, treatment completers (i.e., patients who attended at least 10 sessions; n = 15) demonstrated significant reductions in all PTSD symptom clusters and cocaine use from baseline to end of treatment. Significant reductions in depressive symptomatology, as measured by the Beck Depression Inventory, and psychiatric and cocaine use severity, as measured by the Addiction Severity Index, were also observed. These improvements in PTSD symptoms and cocaine use were maintained over a 6-month follow-up period among completers. The average pre- to posttreatment effect size was 1.80 for PTSD symptoms and 1.26 for drug and alcohol use severity. Baseline comparisons between treatment completers and noncompleters revealed significantly higher avoidance symptoms, as measured by the Impact of Events Scale, and fewer years of education among treatment noncompleters as compared to completers. This study provides preliminary evidence to suggest that exposure therapy can be used safely and may be effective in the treatment of PTSD in some individuals with cocaine dependence. However, the study is limited by the uncontrolled nature of the study design, small number of subjects, and high dropout rate. © 2001 Elsevier Science Inc. All rights reserved.

Keywords: PTSD; Posttraumatic stress disorder; Cocaine; Substance use; Exposure therapy
Fairbank, 1992; cf. Triffleman, Carroll, & Kellogg, 1999) to tolerate exposure without relapse. In addition, it has been suggested that SUD patients may be too cognitively impaired for imagery procedures (Abueg & Fairbank, 1992; Pitman, Altman, Greenwald, Longpre, Macklin, et al., 1991). Several case studies investigating the use of exposure-based treatments in individuals with comorbid PTSD and a variety of SUDs have had mixed results (Keane & Kaloupek, 1982; Mueser & Butler, 1987; Pitman et al., 1991; Vaughan & Tarrier, 1992).

An estimated 30% to 60% of individuals with SUDs meet criteria for comorbid PTSD (Brown, Recupero, & Stout, 1995; Stewart, 1996). These estimates are significantly greater than estimates of PTSD in the general population (8% to 9%; Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995; Hidalgo & Davidson, 2000). Cottler, Compton, Mager, Spitznagel, and Janca (1992) found that cocaine/opiate users had the highest risk for comorbid PTSD and that the rate of PTSD was ten times higher in this group when compared to individuals without cocaine dependence. Many investigators have noted that PTSD/SUD comorbidity is associated with a more severe symptom profile, higher rates of Axis I and II pathology, more severe social impairment, and poorer treatment course and outcome (Back et al., 2000; Brown et al., 1995; Najavits et al., 1998a; Ouimette, Finney, & Moos, 1999; Stewart, Conrod, Pihl, & Dongier, 1999).

The goal of the present study was a preliminary, uncontrolled evaluation of the safety, efficacy, and tolerability of exposure therapy in the treatment of PTSD among a sample of individuals with comorbid PTSD and cocaine dependence. Patient retention and improvement in PTSD severity, cocaine use, and associated features during treatment and at 6 months follow-up were examined. Baseline characteristics of individuals who completed treatment (i.e., attended ten or more sessions) were compared with individuals who did not complete treatment.

2. Methods

2.1. Participants

Participants were 39 treatment-seeking individuals (32 women, 7 men) enrolled in an outpatient psychotherapy development trial designed for the concurrent treatment of PTSD and cocaine dependence. All patients met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for current PTSD and cocaine dependence, and attended at least one therapy session. Completion of ten therapy sessions involved participation in at least three exposure-based therapy sessions. Based on the clinical experience of our group, three exposure-based sessions were considered to be the minimum amount of exposure necessary for therapeutic effect. Therefore, individuals who completed ten or more sessions were defined as therapy completers (n = 24). Exclusionary criteria included psychosis, dissociative identity disorder, dementia, illiteracy, and suicidal or homicidal ideation. Individuals who were medically unstable were also excluded from the study. Participants could be dependent on another substance, but had to identify cocaine as their drug of choice.

2.2. Measures

2.2.1. Substance use assessments

Diagnoses of substance use disorders were made at baseline using the Structured Clinical Interview for the DSM-IV (SCID) (First, Spitzer, Gibbon, & Williams, 1996). The Addiction Severity Index (ASI) (McLellan, Parikh, & Bragg, 1990) was used to measure severity of substance use and impairment in associated areas (e.g., family, medical) at baseline and treatment termination. Urine drug screen (UDS) tests for cocaine, marijuana, and opiates were performed weekly to assess drug use.

2.2.2. Trauma and PTSD assessments

The National Women’s Study (NWS) PTSD Module (Kilpatrick, Resnick, Saunders, & Best, 1989), a structured clinical interview, was employed to screen for Criterion A events and assess PTSD. Reliability and validity of the NWS are adequate (Resnick, Kilpatrick, Dansky, & Best, 1993). The Clinician-Administered PTSD Scale (CAPS) (Blake et al., 1995), a 30-item structured interview, measured frequency, and intensity of Criterion A, B, C and D PTSD symptoms. Research has demonstrated adequate reliability and validity for the CAPS (Blake et al., 1995). Two self-report instruments, the Impact of Events Scale (IES) (Horowitz, Wilner, & Alvarez, 1979) and the Mississippi Scale for PTSD (MISS) (Keane, Caddell, & Taylor, 1997), were also administered weekly to measure PTSD symptoms. IES subscales for intrusion, avoidance, and a total score were computed. Depressive symptomatology was assessed with the Beck Depression Inventory (BDI) (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961).

2.3. Procedure

2.3.1. Evaluations

Eligible participants read and signed an IRB-approved consent form and were interviewed by a trained clinician. The NWS was administered at baseline. The CAPS and ASI were administered at baseline, weeks 4, 8, 12, and 16, and at 6 months follow-up. The IES, MISS, and TLFB were administered weekly and at follow-up. UDS samples were collected at each treatment session. Attendance was reinforced with gift certificates worth $10 given at the end of completing two consecutive scheduled therapy sessions.
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات